Inhibitors of anthrax lethal factor
Graphical abstract
An inhibitor of anthrax lethal factor (1) was discovered. A subsequent SAR and mechanistic study was performed to identify uncompetitive inhibitors of anthrax lethal factor with good cell potency and low cytotoxicity.
Section snippets
Acknowledgments
This work was supported by a grant from the Showalter Foundation. The authors are grateful to Mark Lipton for helpful discussions, Andrew Mesecar for PA, and Jenna Rickus for use of the Flex Station II fluorometer.
References and notes (32)
- et al.
Biochem. Biophys. Res. Comm.
(1998) - et al.
Trends Biochem. Sci.
(2004) - et al.
Cell. Signalling
(2003) - et al.
Bioorg. Med. Chem. Lett.
(2006) - et al.
Bioorg. Med. Chem. Lett.
(2006) - et al.
Bioorg. Med. Chem. Lett.
(2006) - et al.
J. Biol. Chem.
(2003) - et al.
Science
(1998) - et al.
Biochem. J.
(2000) - et al.
Biochem. J.
(2003)
Biochem. J.
Infect. Immun.
Nature
EMBO Reports
ChemBioChem
Nat. Struct. Biol.
Cited by (23)
Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors
2016, Journal of Molecular Graphics and ModellingCitation Excerpt :Antibiotics such as fluoroquinolones are capable of eradicating the bacilli, however, host death from residual toxemia can occur even after B. anthracis is cleared from the system, and there is currently no extant therapeutic modality to directly combat LF-mediated cytotoxicity [6,7]. As B. anthracis continues to pose a significant threat as a biological weapon, various experimental and computational efforts have been focused on identifying small-molecule LF inhibitors as potential drugs as adjunct therapeutics with antibiotics [4,8–33]. Previous computational modeling efforts have been primarily directed toward structure-based virtual screening, pharmacophore mapping, and 3D-QSAR model development [28–33].
D-Proline-based peptidomimetic inhibitors of anthrax lethal factor
2012, European Journal of Medicinal ChemistryCitation Excerpt :Indeed, a possible therapeutic approach envisages the combination of antibiotics with LF inhibitors to clear the active infection while blocking the toxin already present in the cells. There are a number of successful LF inhibitors reported to date [16–21], and important structure–activity studies for understanding binding mode features of chemically diverse inhibitors have been published during the last decade [22,23]. Also, recent reports on potent hydroxamic acid-based LF inhibitors [24,25], and new SAR studies have been reported [26].
Yeast-hybrid based high-throughput assay for identification of anthrax lethal factor inhibitors
2011, Biochemical and Biophysical Research CommunicationsCitation Excerpt :In summary, this study describes a novel LF inhibitor screening system in a high-throughput format. Despite these concerns like differences between yeast and mammalian cells, the screening system reported here has an advantage over existing animal cell-based screens [26,27] in that the hits are specific for LF activity inhibition rather than blocking entry or altering host response to toxin action. Therefore, target identification appears to be straight forward to obtain LF inhibitors.
Efficient production and characterization of Bacillus anthracis lethal factor and a novel inactive mutant rLFm-Y236F
2008, Protein Expression and PurificationInhibitors of anthrax lethal factor based upon N-oleoyldopamine
2008, Bioorganic and Medicinal Chemistry LettersTargeting metalloenzymes for therapeutic intervention
2019, Chemical Reviews